Table 1.
Demographic, clinical, and pathological characteristics of patients by surgical margin status
| Positive Margins (N=1600; 40%) | Negative Margins (N=2451; 60%) | P-value | |
|---|---|---|---|
|
|
|||
| Age, mean ± SD | 61.8 ± 6.4 | 62.3 ± 6.1 | 0.010 |
| Race, n (%) | <0.001 | ||
| White | 862 (54) | 1510 (62) | |
| Black | 645 (40) | 769 (31) | |
| Other | 93 (6) | 172 (7) | |
| Year of Surgery, median (Q1–Q3) | 2004 (1999, 2009) | 2005 (2000, 2010) | 0.002 |
| PSA, median (Q1–Q3) | 7.4 (5.1, 11.4) | 6.0 (4.5, 8.7) | <0.001 |
| Pathological Stage, n (%) | <0.001 | ||
| T2 | 960 (40) | 2109 (86) | |
| T3/T4 | 640 (40) | 341 (14) | |
| Pathological Gleason score, n (%) | <0.001 | ||
| 2–6 | 381 (24) | 1026 (42) | |
| 7 (3+4) | 715 (45) | 818 (33) | |
| 7 (4+3) | 251 (15) | 370 (15) | |
| 8–10 | 253 (16) | 237 (10) | |
| Extracapsular Extension, n (%) | 516 (32) | 263 (11) | <0.001 |
| Seminal Vesicle Invasion, n (%) | 246 (15) | 135 (6) | <0.001 |
| Adjuvant Therapy, n (%) | 92 (6) | 19 (1) | <0.001 |
| Salvage Radiotherapy, n (%) | 235 (15) | 81 (3) | <0.001 |
| Months from RP to BCR, median (Q1–Q3)* | 11.4 (3.6, 34.3) | 21.8 (6.6, 49.8) | <0.001 |
SD=standard deviation; Q1=25th percentile; Q3=75th percentile; RP=radical prostatectomy; BCR= biochemical recurrence
*
Among patients who experienced biochemical recurrence